[JS01] MOU Session - Adult Acute Lymphoblastic Leukemia in Asia
Room 1
March 27 (Thu), 09:00-10:15
TBA
09:00-09:15
Opportunities and challenges in managing adult ALL in Vietnam
Han Viet Trung (Bach Mai Hospital, Vietnam)
09:15-09:30
Adult ALL in Armenia
Armine Farmazyan (Hematology center after Prof. Yeolyan, Armenia)
09:30-09:45
Clinical features, genetic profiling and treatment outcomes of adult acute lymphoblastic leukemia: A prospective multicenter study in Thailand
Weerapat Owattanapanich (Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand)
09:45-10:00
Adult ALL in Korea
Ik Chan Song (Chungnam National University College of Medicine, Korea)
10:00-10:15
Discussion
[SS01] Improving outcomes in challenging Pediatric Leukemia
Room 2
March 27 (Thu), 09:00-10:15
TBA
09:00-09:25
Diagnosis and treatment of Ph-like ALL in children and young adults
Thai Hoa Tran (Université de Montréal, Canada)
09:25-09:50
Advances in the genetics of down syndrome-related myeloid leukemias
Etsuro Ito (Hirosaki University Graduate School of Medicine, Japan)
09:50-10:15
Towards improving outcomes for high risk pediatric acute myeloid leukemia
Todd Cooper (Seattle Children’s Hospital, USA)
[SS02] Overcoming the resistance mechanisms of Multiple Myeloma
Room 3
March 27 (Thu), 09:00-10:15
TBA
09:00-09:25
Immune therapy and the bone marrow microenvironment in multiple myeloma
Hearn Jay Cho (Icahn School of Medicine at Mount Sinai, USA)
09:25-09:50
Mechanisms of antigen escape after T-cell based immunotherapies
Paola Neri (University of Calgary, Canada)
09:50-10:15
Cellular immunotherapy platforms in multiple myeloma
Sung-Hoon Jung (Chonnam National University Medical School, Korea)
[ES01] Understanding the fundamentals of Myelodysplastic Syndrome
KORRoom 4
March 27 (Thu), 09:00-10:15
TBA
09:00-09:25
Tracing the changes: MDS risk stratification
Seo-Yeon Ahn (Chonnam National University Medical School, Korea)
09:25-09:50
Managing MDS with HMAs following the AZA-001 trial
Silvia Park (College of Medicine, The Catholic University of Korea, Korea)
09:50-10:15
Approved MDS treatments beyond HMAs
Junshik Hong (Seoul National University College of Medicine, Korea)
[PL01] Plenary Lecture 01
Room 1+2
March 27 (Thu), 10:30-11:15
TBA
10:30-11:15
Myeloproliferative Neoplasms: 2025 update
Ayalew Tefferi (Mayo Clinic, USA)
[PS01] Presidential Symposium 01
Room 1+2
March 27 (Thu), 11:15-12:00
TBA
11:15-12:00
CAR T-cell therapy for Lymphomas: Current and future trends
Sattva S Neelapu (The University of Texas MD Anderson Cancer Center, USA)
[JS02] EHA-KSH: Acute Myeloid Leukemia - Research and practice
Room 1
March 27 (Thu), 15:25-16:40
TBA
15:25-15:40
Altered transcriptional programmes in AML: The role of aberrant gene regulatory complexes (GRC)
Brian Huntly (University of Cambridge, UK)
15:40-15:55
Treatment of AML in Korea
June-Won Cheong (Yonsei University College of Medicine, Korea)
15:55-16:10
Genetics guiding treatment in AML
Hartmut Döhner (Ulm University Hospital, Germany)
16:10-16:25
The dynamic landscape of AML genetics: From the perspective of the Korean AML/MDS working party study
Jae-Sook Ahn (Chonnam National University Medical School, Korea)
16:25-16:40
Discussion
[SS03] Updates in cancer-associated Venous Thromboembolism
Room 2
March 27 (Thu), 15:25-16:40
TBA
15:25-15:50
How to decide and treat when DOAC should not be standard treatment
Jeffrey I. Weitz (McMaster University, Canada)
15:50-16:15
Managing patients with cancer associated venous thromboembolism
Robert D. McBane II (Mayo College of Medicine, USA)
16:15-16:40
Risk assessment and thromboprophylaxis for cancer-associated VTE
Ingrid Pabinger-Fasching (Medical University of Vienna, Austria)
[SS04] Advancements in Peripheral T-cell Lymphoma: From biological insights to innovative treatments
Room 3
March 27 (Thu), 15:25-16:40
TBA
15:25-15:50
Peripheral T-cell lymphoma: From biology to practice
Owen A O'Connor (University of Virginia Comprehensive Cancer Center, USA)
15:50-16:15
Recent updates and future in the management of R/R PTCL
Won Seog Kim (Sungkyunkwan University School of Medicine, Korea)
16:15-16:40
The development of new agents in T-cell lymphoma
Pier Luigi Zinzani (Università di Bologna, Italy)
[ES02] Basic understanding and application of Artificial Intelligence
KORRoom 4
March 27 (Thu), 15:25-16:40
TBA
15:25-15:50
AI everywhere
Auk Kim (Department of Computer Science and Engineering, Kangwon National University, Korea)
15:50-16:15
Revolutionizing medical documentation: Leveraging ChatGPT and RAG frameworks for optimized scientific writing and clinical interpretation
Sang-Hyun Hwang (University of Ulsan College of Medicine, Korea)
16:15-16:40
Generative AI use case for medical research: HRS (Healthcare data research suite)
Soo-Yong Shin (Head of Research & Chief Privacy Officer, KakaoHealthcare, Korea)
[SS05] Red blood cells in Myeloproliferative Neoplasm
Room 1
March 27 (Thu), 16:55-18:10
TBA
16:55-17:20
Iron metabolism in JAK2-mutant myeloproliferative neoplasm
Radek C. Skoda (Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, USA)
17:20-17:45
Hepcidin in the pathophysiology of and as treatment for polycythemia vera
Yelena Z. Ginzburg (Icahn School of Medicine at Mount Sinai, USA)
17:45-18:10
Anemia and JAK inhibitors
Jean-Jaques Kiladjian (Saint-Louis Hospital, France)
[SS06] Advances and challenges in Histiocytic diseases: A comprehensive update
Room 2
March 27 (Thu), 16:55-18:10
TBA
16:55-17:20
Innovations in HLH therapy: Emapalumab in clinical practice
Carl Allen (Baylor College of Medicine, USA)
17:20-17:45
Navigating pediatric histiocytosis: Advances in first-line MAPK inhibition and targeted therapies
Oussama Abla (The Hospital for Sick Children, Canada)
17:45-18:10
From CRS to IEC-HS: Advancements in understanding and treating hemophagocytic syndromes
Melissa Hines (St. Jude Children’s Research Hospital , USA)
[SS07] Breaking new ground in Acute Myeloid Leukemia
Room 3
March 27 (Thu), 16:55-18:10
TBA
16:55-17:20
Understanding and overcoming resistance in AML: Targeted therapy barriers
Catherine Smith (University of California San Francisco, USA)
17:20-17:45
Exploring immune checkpoint targets beyond PD-1 and PD-L1 in AML
Tae Kon Kim (Vanderbilt University Medical Center, USA)
17:45-18:10
Implementing a functional precision medicine for AML patients
Mika Kontro (Helsinki University Hospital, Finland)
[ES03] Turning ideas into successful Clinical Trial: A practical approach
KORRoom 4
March 27 (Thu), 16:55-18:10
TBA
16:55-17:20
Crafting a successful investigator-initiated study proposal: Key elements and strategies
Young Woo Jeon (College of Medicine, The Catholic University of Korea, Korea)
17:20-17:45
Current Trends of Big Data Research Using the Korean National Health Information Database
Kyung-Do Han (Department of Statistics and Actuarial Science, Soongsil University, Korea)
17:45-18:10
Phase-specific strategies for adverse events management in clinical trials: Best practices in AE documentation and reporting
Jeong-Ok Lee (Seoul National University College of Medicine, Korea)
March 28 (Friday)
[JS03] ASH-KSH: Chronic Myeloid Leukemia - Era of Next-Generation Sequencing
Room 1
March 28 (Fri), 09:00-10:15
TBA
09:00-09:15
Beyond BCR::ABL1-The Role of Genomic Analysis in the Management of CML
Susan Branford (Centre for Cancer Biology, SA Pathology, Australia)
09:15-09:30
Next-Generation Sequencing (NGS) in CML
Jieun Kim (Soonchunhyang University College of Medicine, Korea)
09:30-09:45
What systems biology and AI can teach us about the pathogenesis and therapy of CML
Richard A. Van Etten (University of California Irvine, USA)
09:45-10:00
Recent genomic studies in CML
Hawk Kim (Gachon University College of Medicine, Korea)
10:00-10:15
Discussion
[SS08] TP53 alterations in hematological malignancy: From clonal hematopoiesis to acute leukemia
Room 2
March 28 (Fri), 09:00-10:15
TBA
09:00-09:25
Chronic inflammation as a driver of TP53-mutant leukemic evolution
Yan Liu (Robert H. Lurie Comprehensive Cancer Center, USA)
09:25-09:50
TP53 copy number and protein expression for risk stratification in AML
Joseph D. Khoury (University of Nebraska Medical Center, USA)
09:50-10:15
Molecular characterization of TP53 mutation in AML and high-risk MDS
Peter J.M. Valk (Erasmus MC Cancer Institute, The Netherlands)
[SS09] Advancing the paradigm in Adult Acute Lymphoblastic Leukemia care
Room 3
March 28 (Fri), 09:00-10:15
TBA
09:00-09:25
Is it time to embrace Chemotherapy-Free Regimens in Ph+ ALL
Jae-ho Yoon (College of Medicine, The Catholic University of Korea, Korea)
09:25-09:50
CAR T-Cell Therapy in relapsed/refractory Acute Lymphoblastic Leukemia
Jae Park (Memorial Sloan Kettering Cancer Center, USA)
09:50-10:15
Navigating new horizons: Safety and efficacy of CD7-CAR-T cells in T-ALL/LBL
Yongxian Hu (The First Affiliated Hospital of College of Medicine, Zhejiang University, China)
09:00-09:25
MRD-based therapeutic decisions in AML
Dae Hun Kwag (College of Medicine, The Catholic University of Korea, Korea)
09:25-09:50
MRD-based therapeutic decisions in pediatric ALL
Jung Yoon Choi (Seoul National University College of Medicine, Korea)
09:50-10:15
MRD-based therapeutic decisions in MM
Ji Hyun Lee (Dong-A University College of Medicine, Korea)
[PL02] Plenary Lecture 02
Room 1+2
March 28 (Fri), 10:30-11:15
TBA
10:30-11:15
From ancient origins to modern tools: CD38's evolutionary legacy in science and clinical practice
Fabio Malavasi (University of Torino, Italy)
[ES05] Up-to-date management of Multiple Myeloma
Room 1
March 28 (Fri), 15:05-16:20
TBA
15:05-15:30
Treatment strategies for transplant-eligible newly diagnosed multiple myeloma
Ja Min Byun (Seoul National University College of Medicine, Korea)
15:30-15:55
Treatment of transplant-ineligible MM
Jongheon Jung (National Cancer Center, Korea)
15:55-16:20
Supportive care of MM patients in the new agent era
Sung-Soo Park (College of Medicine, The Catholic University of Korea)
[SS10] Next steps toward enhanced treatment for Pediatric Lymphoid malignancies
Room 2
March 28 (Fri), 15:05-16:20
TBA
15:05-15:30
Overcoming aggressive pediatric non-hodgkin lymphoma
Birgit Burkhardt (University Hospital Münster, Germany)
15:30-15:55
Utilizing NGS MRD as an effective tool in ALL management
Yongmin Tang (Children’s Hospital of Zhejiang University School of Medicine, China)
15:55-16:20
CAEBV, from basic to updated therapeutic options
Seung Min Hahn (Yonsei University College of Medicine, Korea)
[SS11] Driving the future of our CAR
Room 3
March 28 (Fri), 15:05-16:20
TBA
15:05-15:30
Current status of "off-the-shelf" allogeneic CAR in the treatment of acute lymphoblastic leukemia
Reuben Benjamin (King’s College London, UK)
15:30-15:55
Allogeneic CAR-T cells engineered with gene-editing strategies for the treatment of B-cell non-Hodgkin lymphomas
Boyu Hu (University of Utah, USA)
15:55-16:20
Memory-like NK cells armed with a neoantigen-specific CAR
Rizwan Romee (Harvard Medical School, USA)
[ES06] Patient care in Cytopenia consultations: Best practices for hematologists
KORRoom 4
March 28 (Fri), 15:05-16:20
TBA
15:05-15:30
Anemia
Eun sang Yu (Korea University College of Medicine, Korea)
15:30-15:55
Thrombocytopenia
Yoo Jin Lee (Ulsan University Hospital, Korea)
15:55-16:20
Neutropenia
Seonggyu Byeon (Gachon University College of Medicine, Korea)
[JS04] Asia Session - Dawn of CAR-T therapy: Asian perspective
Room 1
March 28 (Fri), 16:35-17:50
TBA
16:35-16:50
Current status of CAR-T treatment in Taiwan
Tai-Chung Huang (National Taiwan University Hospital, Taiwan)
16:50-17:05
Challenges in CAR-T treatment in Singapore
William YK Hwang (National Cancer Centre Singapore, Singapore)
17:05-17:20
Barriers and paths in CAR-T therapy in China
Kailin Xu (The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China)
17:20-17:35
Present and future of CAR-T therapy in Korea
Dok Hyun Yoon (University of Ulsan College of Medicine, Korea)
17:35-17:50
Discussion
[SS12] Cutting-edge Diagnostic Techniques in hematology
Room 2
March 28 (Fri), 16:35-17:50
TBA
16:35-17:00
NGS-based MRD in AML
James L. Zehnder (Stanford University School of Medicine, USA)
17:00-17:25
Exploring the transcriptional and protein landscape of immune cells with CITE-seq
Jennifer A. Foltz (Washington University School of Medicine, USA)
17:25-17:50
CML drug resistance profiling using CRISPR-Cas9
Hyongbum Kim (Yonsei University College of Medicine, Korea)
[SS13] Innovations in aplastic anemia and Paroxysmal Nocturnal Hemoglobinuria
Room 3
March 28 (Fri), 16:35-17:50
TBA
16:35-17:00
Finding a better immunosuppressive treatment in SAA
Fengkui Zhang (Chinese Academy of Medical Sciences and Peking Union Medical College, China)
17:00-17:25
Alternative donor HSCT in SAA
Ho Joon Im (University of Ulsan College of Medicine, Korea)
17:25-17:50
Optimal treatment of PNH in the era of proximal complement inhibitors
Rosario Notaro (Core Research Laboratory, ISPRO, Italy)
[ES07] Treatment of indolent & Hodgkin Lymphoma
Room 4
March 28 (Fri), 16:35-17:50
TBA
16:35-17:00
Immunotherapy in follicular lymphoma
TBA 17:00-17:25
BTK inhibitions in waldenstroms macroglobulinemia
Myung-won Lee (Chungnam National University College of Medicine, Korea)
17:25-17:50
Treatment for older patients with Hodgkin lymphoma
Hyunsoo Cho (Yonsei University College of Medicine, Korea)
March 29 (Saturday)
[JS05] Asia Session - MRD and Immunotherapy in Multiple Myeloma: Collaborative insights from Korea and Japan
Room 1
March 29 (Sat), 09:00-10:15
TBA
09:00-09:15
Current status of MRD assessment in Japan
TBA 09:15-09:30
Current status of MRD assessment in Korea
Saeam Shin (Yonsei University College of Medicine, Korea)
09:30-09:45
Immunotherapy (bispecific Abs or CAR-T therapy) for MM in Japan
TBA 09:45-10:00
Current status and experience of bispecific Abs for MM in Korea
Jun Ho Yi (Chung-Ang University College of Medicine, Korea)
10:00-10:15
Discussion
[SS14] Deciphering blood Coagulation Tests
Room 2
March 29 (Sat), 09:00-10:15
TBA
09:00-09:25
Investigative approaches to unexplained bleeding
Alessandro Casini (University Hospitals of Geneva, Switzerland)
09:25-09:50
Optimal testing strategies for suspected platelet disorders
Christopher Ward (University of Sydney, Australia)
09:50-10:15
Thrombophilia testing in clinical practice: Indications, challenges, and current approaches
Hee-Jin Kim (Sungkyunkwan University School of Medicine, Korea)
[SS15] Immunotherapy in B-Cell Lymphoma: Current status and emerging approaches
Room 3
March 29 (Sat), 09:00-10:15
TBA
09:00-09:25
Advancing CD3xCD20 bispecific Abs: Integration in first-line treatment of DLBCL
Catherine Thieblemont (Hôpital Saint-Louis, France)
09:25-09:50
Emerging bispecific antibodies for B-Cell lymphoma: New targets and future directions
Youngil Koh (Seoul National University College of Medicine, Korea)
09:50-10:15
Management of toxicity of bispecific antibody for B-cell lymphomas
Koji Izutsu (National Cancer Center Hospital, Japan)
[ES08] Supportive care: Management of infections and iron overload
KORRoom 4
March 29 (Sat), 09:00-10:15
TBA
09:00-09:25
Invasive fungal infections in hematologic disease: Prophylaxis and treatment
Sung-Yeon Cho (College of Medicine, The Catholic University of Korea, Korea)
09:25-09:50
CMV infections after HSCT: Prophylaxis and treatment
Haerim Chung (Yonsei University College of Medicine, Korea)
09:50-10:15
Iron overload and iron chelation therapy
Ga-Young Song (Chonnam National University Medical School, Korea)
[PL03] Plenary Lecture 03
Room 1+2
March 29 (Sat), 10:30-11:15
TBA
10:30-11:15
New discoveries that will shape future therapies in Chronic Myeloid Leukemia
Timothy Hughes (South Australian Health and Medical Research Institute (SAHMRI), Australia)
